Thetford Mines, Quebec – TheNewswire – KDA Group Inc. (TSXV:KDA) (” KDA ” or the ” Corporation “) is very happy to announce that the organization has finalized a letter that is exclusive of (the ” LOI “) with ZoomMed health Inc. (” ZoomMed Medical “) when it comes to acquisition of this ZRx Prescriber technology asset composed of its platform and supply codes (the ” ZRx Prescriber resource “). KDA is designed to develop and make use of the ZRx Prescriber resource in the usa and Europe.
KDA has consented to get the ZRx Prescriber resource in consideration for 20,000,000 course a stocks https://fastcashcartitleloans.com/payday-loans-ok/ of the share money (the ” deal “) on conditions and terms consented to into the LOI. KDA and ZoomMed healthcare are supply’s size events.
The proposed Transaction is anticipated to close. Associated with the closing, KDA will finish its diligence that is due and events will come right into a valuable asset purchase contract and just about every other agreements necessary and needed by such deal or required by regulatory authorities, including in specific an understanding for the development and commercialization of this ZRx Prescriber resource.
“This deal will advantageously propel technical medical solutions to your vast U.S. and European market, as well as accelerating the growth of our Elixir420 platform. The expertise of KDA’s management and more especially its subsidiary group, LIV Agency Inc., will surely be a vital element that is strategic to your success,” explained Sylvain Duvernay, ceo of KDA.
“The objective of y our subsidiary would be to offer quality all the time through the circulation of academic programs and communications within the field that is medical through the development to your utilization of techniques wanted to big pharmaceutical businesses to boost client wellness. Utilizing the ZRx technology platform, we are in a position to expand our solution offerings to healthcare experts and clients over the vast U.S. Continue reading